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Abstract
Determining the chromosomal phase of pairs of sequence variants – the arrangement of
specific alleles as haplotypes – is a routine challenge in molecular genetics. Here we de-
scribe Drop-Phase, a molecular method for quickly ascertaining the phase of pairs of DNA
sequence variants (separated by 1-200 kb) without cloning or manual single-molecule dilu-
tion. In each Drop-Phase reaction, genomic DNA segments are isolated in tens of thou-
sands of nanoliter-sized droplets together with allele-specific fluorescence probes, in a
single reaction well. Physically linked alleles partition into the same droplets, revealing their
chromosomal phase in the co-distribution of fluorophores across droplets. We demonstrat-
ed the accuracy of this method by phasing members of trios (revealing 100% concordance
with inheritance information), and demonstrate a common clinical application by phasing
CFTR alleles at genomic distances of 11–116 kb in the genomes of cystic fibrosis patients.
Drop-Phase is rapid (requiring less than 4 hours), scalable (to hundreds of samples), and ef-
fective at long genomic distances (200 kb).
Introduction
Sequencing and genotyping identify the alleles that are present in a diploid genome without re-
vealing their arrangement as haplotypes. Knowing the chromosomal phase of genomic se-
quence variants is often important for genetic analysis and for fully exploiting the potential of
techniques such as genome engineering and allele-specific expression analysis.
We briefly describe four genetics research scenarios, among many others, in which phase in-
formation is important. (i) Compound heterozygosity. Whenever a gene has multiple deleterious
alleles in the same individual, or in a cancer, determining whether such alleles are present on the
same chromosomal copy of the gene (in cis) or the opposite copy (in trans, potentially inactivat-
ing both copies) is central to genetic interpretation. (ii) Allele-specific expression analysis pro-
vides precise ways of measuring the effects of cis-acting regulatory variants on nearby genes
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[1,2]—but its effective use requires information about chromosomal phase to evaluate the direc-
tion of effect (increased or decreased expression) of regulatory variants. (iii) Parent-of-origin
analysis of new mutations is important in genetic counseling and in research about male and fe-
male mutation rates and effects of paternal age; such analysis is today often limited to research
scenarios in which three generations can be sequenced [3,4], or to the small subset of mutations
that are near inherited variants [5]. (iv) Genome engineering is beginning to attain widespread
use as a way to evaluate the functional consequence of genome variants [6–9]. In humans and
other species with extensive heterozygosity, it will often be important to know the chromosomal
phase of experimenter-made genome edits, which affect a random chromosomal copy, with re-
spect to the rare and common functional variants that are already present at a locus of interest.
For rare variants, new mutations, and genome edits, chromosomal phase cannot be inferred
by population-based statistical methods; even for common polymorphisms, statistical infer-
ence of phase is only probabilistically accurate. Family-based data are useful for phasing, but
are available only in select contexts. Thus, molecular methods for phasing have been important
in both research and clinical applications.
Existing molecular methods for phasing pairs of variants involve long-range PCR, cloning,
and/or manual dilution to single-molecule concentrations. An important class of methods has in-
volved single-molecule dilution (SMD) [10] which can be followed by PCR and mass spectrome-
try [11], or by amplification and Sanger sequencing [12],[13]. SMD is quite effective, though SMD
requires manual dilutions of DNA samples to single-molecule concentrations. Another class of
methods involves long-range PCR, which can be combined with intra-molecular ligation [14], or
use allele-specific primers [15,16], or be followed by cloning and Sanger sequencing, to detect
linked alleles. Long-range PCR can also be successful, though is limited to the scale of PCR ampli-
cons (generally< 20 kb). When the value of genome-wide information justifies the investments
in constructing clone libraries, libraries can be constructed and subjected to high-throughput se-
quencing in barcoded pools [17]. Cloning-free methods utilizing SMD (dilution of genomic DNA
into sub-haploid quantities across many individual wells) followed by multiple displacement am-
plification, barcoding, and NGS have also recently been described [18,19].
The day-to-day use of molecular phasing approaches has been limited by cost and time re-
quirements (cloning, manual limiting dilution) or genomic range (PCR). A key need is for fast,
low-cost approaches that a scientist could apply in an afternoon and to many samples at once.
Recent innovations in microfluidics allow biochemical reactions to be quickly partitioned
into thousands of nanoliter-sized droplets (aqueous compartments in an oil-aqueous emul-
sion) and allow fluorescence signals in such droplets to be quickly quantified [20]; devices for
making and analyzing droplets are now available in many research labs. Droplets allow single-
molecule dilution to be accomplished within individual reaction vessels (wells), a feature which
we hypothesized could be combined with allele- fluorescence probes (from pairs of loci) and
customized statistical analysis methods to support rapid, inexpensive molecular phasing.
Here we describe Drop-Phase, a method for rapidly phasing pairs of genomic sequences in
sets of 1 to 96 genomes, at low cost and in a few hours’ work.
Material and Methods
Digital droplet PCR
Droplet digital PCR (ddPCR) involves the use of readily generated oil/aqueous reverse emulsions
to partition a reaction into thousands of tiny, nanoliter-volume reaction compartments [20].
Microfluidics support the creation of monodisperse emulsions in which droplets have a uniform
volume [20]; such emulsions are created in about two minutes (per reaction) using “droplet gen-
eration” devices that are now available in many research labs (Bio-Rad Laboratories, Hercules,
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CA, USA). We performed ddPCR as described in earlier studies [20], with a few important differ-
ences. First, we used wide-bore pipette tips during gDNAmanipulations, and used gentle reac-
tion mixing to preserve the longer fragments present in gDNA samples. Second, in some
experiments in which longer-range (>30 kb) phasing was desired, we extracted the DNA using
methods (described below) that maximize the yield of long fragments. Finally, in contrast to
standard ddPCR analysis, in which gDNA is digested into smaller fragments using a restriction
enzyme, we used undigested DNA (except in control experiments, as described below).
For this study, droplet digital reactions consisted of gDNA, FAM, and HEX fluorescent hy-
drolysis probe assays and ddPCR Supermix for Probes (no dUTP)(Bio-Rad). gDNA was added
to the reactions at ~650 pg/μL (200 human haploid targets/μL) as determined by A260 measure-
ments from a NanoDrop 8000 spectrophotometer (Thermo Scientific, Waltham, MA). The
Bio-Rad droplet generator emulsifies reaction mixtures into 0.85 nL droplets, which were
transferred into 96 well plates (Eppendorf, Hamburg, DE), sealed with a pierceable foil heat
seal (Bio-Rad), and cycled in a C1000 thermal cycler (Bio-Rad) using one of the following two
protocols: 1) 95°C for 10 min (1 cycle), (94°C for 30 s, 60°C for 1 min) for 40 cycles, 98°C for
10 min (1 cycle) or 2) 95°C for 10 min (1 cycle), (94°C for 30 s, 55°C for 1 min) for 40 cycles,
98°C for 10 min (1 cycle), for the “mile marker” and CFTR phasing experiments, respectively.
Ramp rates were set to 2.0°C/s. The droplets were read using a QX200 droplet reader and data
analyzed using QuantaSoft v1.4.0.99 (Bio-Rad). The QuantaSoft software contains an embed-
ded table that includes columns for ‘concentration’ (total concentration of targeted sequences)
and ‘linkage’ (concentration of linked sequences), which are reported in copies/μL.
Samples
All cell lines and DNA samples were obtained from the Coriell Institute for Medical Research
under an approved material transfer agreement (MTA) and assurance form. Sample GM18916
is an Epstein-Barr virus transformed B-lymphocyte cell line from the Yoruba in Ibadan, Nige-
ria and was part of the International HapMap Project [21], and was used for the mile marker
experiment. This cell line was passaged in Roswell Park Memorial Institute medium 1640 sup-
plemented with 2 mol/m3 L-glutamine (Sigma–Aldrich, St. Louis, MO, USA) and 15% fetal bo-
vine serum (Corning Inc., Corning, NY, USA).
The cystic fibrosis cell lines derived from Epstein-Barr virus transformed B-lymphocytes in-
cluded: GM11286 and GM11274, which were determined to have c.1652G>A (p.Gly551Asp) and
c.1521_1523delCTT (p.Phe508del) variants [22]; GM11279, which was determined to have
129G>C (promoter), c.350G>A (p.Arg117His), and c.1521_1523delCTT (p.Phe508del) variants
[23]; GM11472, which was characterized to have c.1210–12T[7], c.1210–12T[9], c.3909C>G (p.
Asn1303Lys), and c.4046G>A (p.Gly1349Asp) variants [24,25] (c.4046G>A is also referred to as
c.4178G>A in some dbSNP databases); and GM13591, which was characterized to have
c.350G>A (p.Arg117His), c.1210–12T[5], c.1210–12T[9], and c.1521_1523delCTT (p.Phe508del)
variants [26]. These cystic fibrosis cell lines were propagated in the same medium as GM18916.
One untransformed fibroblast cell line, GM03465, was included in the study, and was char-
acterized to have c.1652G>A (p.Gly551Asp) and c.1521_1523delCTT (p.Phe508del) variants
[22]. This cell line was passaged in Eagle's Minimum Essential Medium with Earle's salts sup-
plemented with nonessential amino acids (Sigma—Aldrich), 2 mM L-glutamine (Sigma–
Aldrich), and 15% fetal bovine serum (Corning Inc.).
Assays
The assays used in the mile marker and CFTR phasing experiments are described in S1 Table and
S2 Table, respectively. All primers and Iowa Black quenched probes (IABkFQ) were ordered from
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Integrated DNA Technologies (Coralville, IA, USA), whereas all TaqMan-MGB probes were or-
dered from Life Technologies (Carlsbad, CA, USA). The targeted residue(s) of interest is shown as
a lowercase letter. The concentrations of the assay components were 900 nM, 250 nM, and 1000
nM for primers, probe, and dark probe, respectively. Non-fluorescent (“dark”) competitor probes
were only used in the phasing assays to reduce cross-reactivity with the non-targeted allele.
Sample extraction
GM18916 cells were pelleted at 250 × g for 5 min, washed with 1X phosphate buffered saline
(PBS), pelleted again at 250 × g for 5 min, and resuspended in 1X PBS to a final concentration
of approximately 7 × 106 cells/mL as measured by TC10 Automated Cell Counter (Bio-Rad).
The cells were split into 40 μL aliquots, each with a total cell count of approximately 2.8 × 105
cells. Cells were processed for DNA extraction using either polysaccharide precipitation–based
chemistry (PrepFiler Forensic DNA Extraction Kit, Life Technologies) or silica column–based
chemistry (DNeasy Blood and Tissue Kit, Qiagen, Valencia, CA, USE).
Polysaccharide precipitation
A 40 μL sample of 7 × 106 cells/mL in 1× PBS was extracted using the PrepFiler Forensic DNA Ex-
traction Kit (Life Technologies). The manufacturer’s recommended protocol was used, with the fol-
lowing exceptions: sample lysis incubation was reduced from the recommended 20 min at 70°C to
10 min with no shaking of the sample during incubation; any mixing and/or washing of the sam-
ples by vortexing was replaced with gentle end-over-end inversion except for the mixing step im-
mediately following the addition of 180 μL isopropyl alcohol, which was performed on the lowest
rpm setting of a vortex mixer; centrifugation of samples was kept to brief spins only; and any trans-
fer of sample after cell lysis was performed using only wide-bore pipette tips (Rainin, a Mettler To-
ledo company, Oakland, CA, USA). DNAwas eluted in 50 μL of kit-provided elution buffer.
Silica columns
A 40 μL sample of 7 × 106 cells/mL in 1× PBS was extracted using the DNeasy Blood and Tissue
Kit (Qiagen). The manufacturer’s recommended protocol was used with the following exceptions:
160 μL of 1× PBS was added to the 40 μL sample to bring the sample volume to 200 μL before
adding 200 μL of buffer AL with proteinase K; after adding buffer AL with proteinase K, the sam-
ple was mixed with gentle end-over-end inversion; and any transfer of the sample after cell lysis
was performed using wide-bore pipette tips (Rainin). DNA was eluted in 200 μL of AE buffer.
Calculation of linkage
Detection of linkage is based on the observation that presence of linked DNAmolecules will in-
crease the number of double-positive droplets relative to the number expected due to chance
(Fig. 1). We describe the mathematical calculation of linkage in S1 Note. Linkage can be mea-
sured in absolute terms (the absolute concentration of linked molecules) or in relative terms
(the percent of all molecules that are linked). In this manuscript, we focus on the percent of all
molecules that are linked, as this measurement is not affected by DNA input concentration and
is therefore a property of the DNA sample under analysis.
Controls for determining linkage
We utilized three different strategies for negative controls depending on the experiment. For
the experiment in which we confirmed the phase of variants that had been inferred from inher-
itance data, we used restriction enzymes to specifically cut the DNA sequences between the
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Fig 1. Drop-Phase schematic. A genomic DNA sample is emulsified into aqueous droplets in an oil-aqueous reverse emulsion. Allele-specific fluorescence
probes (FAM, blue; and HEX, green) are used to detect alleles at two different loci. Following PCR, the droplets are positive for one fluorophore (blue or
green), positive for both fluorophores (orange), or positive for neither fluorophore, depending on the alleles they contained at the beginning of the reaction. (a)
Trans-configured alleles partition independently into droplets. Co-partitioning (orange) is therefore governed by chance. (b) Cis-configured alleles tend to co-
segregate into the same droplets, because they are physically linked; co-partitioning greatly exceeds chance expectation. (c) Restriction digest at a site
between the cis-configured alleles abolished co-partitioning of the two alleles; co-partitioning again occurs to the extent expected by chance.
doi:10.1371/journal.pone.0118270.g001
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heterozygous SNPs being phased. In the CFTR phasing experiment, we assembled four unique
duplexes to cover all possible combinations for a pair of heterozygous SNPs. By design, given
sufficiently intact DNA, two of the duplexes will be linked and provide the diplotype of the re-
gion, whereas the other two will not be linked (negative control). Failure to measure a differ-
ence in the percentage of linked molecules between the linked (n = 2) and unlinked (n = 2)
duplexes suggests the DNA between the loci is too fragmented to confirm the phase of the re-
gion. In the “mile marker” analysis of linkage as a function of genomic distance (Fig. 2) the
negative controls were comprised of duplex assays in which individual mile marker assays were
paired with an assay targeting the EIF2C1 gene on a different chromosome (chromosome 1).
Results
Drop-Phase measures the co-partitioning of DNA sequences into
droplets
Drop-Phase utilizes droplet digital PCR (ddPCR), which involves subdividing a reaction mix-
ture into thousands of nanoliter-sized aqueous droplets in an oil-aqueous emulsion, amplifying
DNA within the droplets, and then counting the droplets that contain the product of interest
[20,27,28]. Microfluidic devices for droplet generation and analysis are widely used today
[29–31]. To simultaneously evaluate the presence of two sequences of interest—for example,
two SNP alleles at different loci—we use multiple fluorescence reporters (e.g. FAM and HEX
fluorophores). Drop-Phase determines genomic phase by analyzing the extent to which alleles
at two different genomic loci reside in the same droplets. Our approach is based on a simple
idea: when two alleles are physically linked, they tend to partition into the same droplets.
In each experiment, a genomic DNA sample (10–20 ng) is partitioned into about 20,000
aqueous droplets in an oil/aqueous reverse emulsion (<2 minutes); both loci are amplified
within the droplets in the presence of allele-specific fluorescence probes that report on the pres-
ence of alleles of interest (<90 minutes); and the resultant fluorescence signals are detected in
each droplet (<2.5 minutes per sample).
Drop-Phase results are consistent with inheritance
We first performed a simple proof-of-concept experiment by chromosomally phasing four
pairs of heterozygous SNPs in father-mother-offspring trios for whom the phases of these SNPs
could be independently established by inheritance. In experiments in which the fluorescent
probes detected alleles that resided on different chromosomal copies (“trans-configured” alleles,
as established by inheritance from different parents), the fluorescence signals were distributed
independently across droplets, co-localizing only to the extent expected by chance (p> 0.1 by
chi-square test in each case; Fig. 1a). When the fluorescence probes detected alleles that resided
on the same chromosomal copy (“cis-configured” alleles, established by inheritance from the
same parent), the number of droplets positive for both fluorophores greatly exceeded chance
expectation (p< 10–16 in each case; Fig. 1b). For SNPs at genomic distances of a few kilobases,
most droplets that were positive for one fluorophore were positive for both fluorophores.
To confirm that this enrichment of double-positive droplets was due to physical linkage of
the alleles, we digested the DNA with a restriction enzyme specific to a site between the two
loci before distributing the genomic DNA into droplets (Fig. 1c). Digestion greatly reduced the
frequency of double-positive droplets relative to the undigested sample (p< 10–6) (Fig. 1c).
This result confirmed that the co-partitioning in the earlier experiment (Fig. 1b) was due to
physical linkage of the SNP alleles (Fig. 1c).
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Fig 2. Evaluation of the relationship of physical linkage to genomic distance, using polysaccharide precipitation-extracted DNA. (a) In this analysis,
FAM-labeled “mile marker” assays targeting sequences at different distances (1–210 kb) from the RPP30 anchor sequence were paired with a HEX-labeled
assay specific to the RPP30 anchor sequence. Control assays utilized an anchor assay sequence in EIF2C, which resides on another chromosome. (b) The
percentage of linked molecules at each genomic distance is shown as a function of distance. Means (of triplicate measurements) and 95% confidence
intervals are shown.
doi:10.1371/journal.pone.0118270.g002
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Similarly definitive and accurate determinations of chromosomal phase were achieved for
four pairs of heterozygous SNPs (spanning 1–40 kb) assayed in seven individuals in 100% of as-
says (14/14). These data agreed with the prediction from inheritance, indicating that at least at
modest genomic distances (1–40 kb), Drop-Phase can quickly and reliably phase pairs of SNPs.
The physical range of analysis is limited primarily by DNA fragment size
We next sought to evaluate the genomic distance at which physical linkage or chromosomal
phase can be established by Drop-Phase. Because the extraction of genomic DNA causes chro-
mosomes to fragment into smaller pieces, most genomic DNA samples contain DNA segments
of various sizes. Even when two DNA sequences (alleles) are physically linked in the proband’s
genome, those sequences will be physically linked on only some of the DNA fragments under
analysis. The greater the genomic distance separating the DNA sequences, the smaller the frac-
tion of DNA fragments that will contain both sequences. It was therefore important to under-
stand the mathematical and empirical relationships among genomic distance, DNA
fragmentation, and co-partitioning in droplets.
DNA fragmentation limits the extent to which cis-configured sequences will co-localize.
The more fragmented a DNA sample is, the smaller the fraction of DNA molecules that will
contain both sequences in a physically linked form, and the larger the fraction that will bear the
sequences individually. For any specific DNA sample, we define %linkage as the percentage of
all DNAmolecules containing sequence A that also contain sequence B. If A and B are unlinked
in the donor’s genome—for example, if they are alleles that are trans-configured (on different
chromosomal copies)—then%linkage should be zero. We derived a mathematical formula for
estimating%linkage from the numbers of (A+B+), (A+B-), (A-B+), and (A-B-) droplets in a
Drop-Phase experiment (S1 Note, S1 Fig.). Note that when%linkage is very small, a sample in
which two alleles are cis-configured may become indistinguishable from a sample in which the
alleles are trans-configured. This scenario defines the detection limit of Drop-Phase.
To understand empirically the limitations of linkage and phasing analysis in droplets, we
designed assays to measure%linkage at a series of genomic distances (1, 10, 33, 60, 100, 150,
and 210 kb) from a fixed marker (Fig. 2a). (For this experiment, we utilized non-polymorphic
sequences, since our goal was not to phase but simply to measure the physical intactness of ge-
nomic DNA in a simple way.) We then used these assays to evaluate %linkage as a function of
distance in genomic DNA samples isolated by two common approaches: silica-based column
(DNeasy, Qiagen) and polysaccharide-based precipitation onto magnetic particles (PrepFiler,
Life Technologies). In genomic DNA derived by the polysaccharide-based precipitation, link-
age was readily recognized at all distances tested: at 60 kb,%linkage was approximately 42%;
even at 210 kb,%linkage was approximately 5% and still clearly distinguishable from control
analyses of unlinked loci from different chromosomes (Fig. 2a,b; p< 10–20 at each tested dis-
tance for the linked loci; p> 0.1 at each tested distance for unlinked loci, by Pearson chi-square
test). By contrast, in DNA samples derived from silica-based columns, linkage could be reliably
detected only out to about 60 kb (S2 Fig.). Thus, droplets can be used to analyze linkage and
phase at substantial genomic distances even when DNA is extracted using conventional kit-
based strategies. (Unconventional extraction methods might allow analysis at even longer ge-
nomic distances, but our emphasis here is on easy, scalable methods.)
Drop-Phase in an example application: compound heterozygosity
We next sought to evaluate the utility and efficacy of this approach in a common, real-world ap-
plication: ascertaining the chromosomal phase of deleterious variants across the CFTR gene,
which spans 189 kb. Recessive, non-complementing alleles of CFTR are the most common cause
Chromosomal Phasing in Droplets
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of congenital genetic illness in populations with European ancestry. Individuals with one compro-
mised CFTR copy are carriers; individuals with both CFTR copies compromised have cystic fibro-
sis [32]. Nearly 2,000 variants have been described in CFTR, of which 127 (mostly rare) variants
are thought to be pathogenic [33]. Strongly compromised CFTR alleles include ΔF508 (one of the
first Mendelian recessive variants discovered by positional cloning [34–36]) and c.1652G>A;
these variants are pathogenic when trans-configured, as this arrangement leaves an individual
with no functional copy of the gene. About 3% of individuals with European ancestry are carriers
of ΔF508, which therefore frequently appears in individuals and families together with other
CFTR variants [33]. Some milder CFTR variants are benign when present alone, but when ar-
ranged in ciswith other such variants, can form a more compromised haplotype that fails to com-
plement the more common ΔF508 allele [37,38]. An example of a compromised haplotype of
CFTR involves the combination of the c.350G>A protein-coding variant with the intronic
c.1210–12T[5] repeat expansion polymorphism [37]. Understanding how these and other variants
are arranged onto haplotypes is important for diagnostics and preconception carrier screening.
We analyzed genomic DNA derived from cell lines from six cystic fibrosis patients; each of
these patients was previously known to be heterozygous for two to four CFTR variants (nine vari-
ants total, across the six patients, because several variants were shared by multiple patients) (Meth-
ods). The identities and genomic locations of these variants are shown in Fig. 3a. The genomic
distance separating pairs of variants heterozygous in the same individual ranged from 12 to 116 kb.
For each of the six variant pairs tested, we tested for all four possible allelic configurations.
More specifically, in an Aa:Bb compound heterozygote, we tested for the haplotypes A-B, A-b,
a-B, and a-b. Note that this involves some redundancy (because the existence of an A-B haplotype
implies the existence of an a-b haplotype on the other chromosome) (Fig. 3b). Such redundant as-
says offered opportunities to critically evaluate Drop-Phase, since the inference (for example) of
an A-B and an A-b haplotype in an Aa:Bb compound heterozygote must be incorrect.
For all (13/13) variant pairs heterozygous in any of the six individuals, we were able to infer
both haplotypes (Table 1). Within each individual, results were in every case internally consistent
in the sense that the inferred haplotypes contained opposite alleles (Table 1). In addition, we
found that these haplotype inferences were in each case consistent with these individuals’ known
status as cystic fibrosis patients. Three of the six patients (GM11286, GM11274, and GM03465)
had recessive loss-of-function variants in the trans configuration (ΔF508 on one chromosome;
c.1652G>A on the other chromosome). Two other patients (GM13591 and GM11279) had
ΔF508 trans-configured to a complex haplotype of multiple milder variants (cis-configured
[350G>A; 1210–12T(5)]), which in one of these individuals (GM11279) was also cis-configured
to 129G>C. The sixth individual (GM11472) had two multi-variant haplotypes ([c.3909C>G;
1210–12T(9)] on one chromosome, and [c.4046G>A; 1210–12T(7)] on the other chromosome).
The varied genomic spacing among the variant pairs (11–116 kb) made it possible to ana-
lyze how measurements of physical linkage related to genomic distance (Fig. 3c). Assay pairs
for the two closest variants (c.1521_1523 and c.1210–12T(5_9), separated by 11 kb), gave the
greatest percentage of linked copies (77%), whereas assay pairs for the two most distant vari-
ants (c.1210–12T(5_9) and c.4046, separated by 116 kb) gave the smallest percentage of linked
copies (18%), although this was still far greater than the largest percentage in any unlinked case
(< 2%). Moreover, across all pairs of assays, measurements of physical linkage closely followed
the expected exponential relationship between genomic distance and physical linkage (Fig. 3c).
Robustness of Drop-Phase to SNP assay designs
We sought to make Drop-Phase easy, scalable, and functional for almost any pair of sequence
variants. A potential challenge in discriminating SNPs arises when a fluorescence reporter
Chromosomal Phasing in Droplets
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Fig 3. PhasingCFTR variants in the genomes of cystic fibrosis patients. (a) Locations and genomic
distances separating the variants along theCFTR gene in the tested cell lines. (b) Assembly of four duplex
assays to redundantly evaluate phase of screened variants. (c) Physical linkage of CFTR variants as
measured by Drop-Phase, as a function of genomic distance (horizontal axis). Blue diamonds: allele-pairs
inferred to be cis-configured; purple squares: allele-pairs inferred to be trans-configured. The black line is an
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(such as allele-specific hydrolyzable probes designed to a “targeted” allele) cross-reacts with the
non-targeted allele at an appreciable rate. In many such cases, such cross-reaction resulted in
the presence of additional clusters of droplets with intermediate levels of fluorescence. Al-
though specificity can be achieved with careful assay design, such as the use of “dark” (non-
fluorescent) competitor probes to reduce cross-reactivity, we sought to enhance the robustness
of Drop-Phase to cases in which the assays are somewhat responsive to a non-targeted allele.
Assays that fluoresce in response to both targeted and non-targeted alleles result in more
complex populations of droplets; when both SNP assays have this property, up to 16 (24) differ-
ent patterns of fluorescence will be detected, depending on the presence or absence in each
droplet of targeted (A, B) alleles and non-targeted (a, b) alleles. These patterns are readily dis-
tinguished on a droplet-intensity scatter plot (Fig. 4, S3 Fig., S4 Fig.). For example, consider a
heterozygous site (A/a) analyzed using a FAM-labeled probe that targets the A allele but also
responds to the a allele at a lower intensity (due to a lower rate of probe hybridization and hy-
drolysis). Droplets containing only amplicons with the A allele exhibit the highest level of FAM
fluorescence (Fig. 4c-f, S3 Fig., S4 Fig.; note the two blue and two orange clusters across the
top), whereas droplets containing a mixture of amplicons with the two alleles (A and a) exhibit
a lower level of FAM fluorescence (Fig. 4c-f, S3 Fig., S4 Fig.). Droplets containing only the non-
targeted a allele exhibit a much lower level of fluorescence, and droplets containing neither al-
lele have the lowest FAM fluorescence (Fig. 4c, d, S3 Fig., S4 Fig.; note the clusters shown in
gray and green). An equivalent set of relationships characterizes the other fluorophore (HEX)
and the other locus (B/b) (Fig. 4, S3 Fig., S4 Fig.).
To phase sequence variants, it is necessary only to distinguish those droplets that are posi-
tive for the targeted allele from those that lack the targeted allele, i.e., to distinguish A-only and
A+a droplets from a-only and 0 droplets, and B-only and B+b droplets from b-only and 0
droplets. This is readily accomplished by treating the 16 droplet populations (clusters) as four
meta-populations (meta-clusters; shown in blue, green, orange, and gray in Fig. 4); convenient-
ly, these four meta-populations correspond to the ways in which the droplet intensities already
cluster in two-dimensional fluorescence space (Fig. 4). Surprisingly, we found that such cross-
reacting assays actually provided additional information, because in such cases a single duplex
assay could identify all four linked species (AB, Ab, aB, and ab) (Fig. 4c-f).
exponential curve fit to the cis-configured allele-pairs. Four duplex assays were performed per variant pair.
Variants were classified as cis- or trans-configured based on measured positive linkage or lack of linkage,
respectively. Samples were analyzed in duplicate.
doi:10.1371/journal.pone.0118270.g003
Table 1. Haplotypes formed by CFTR variants in six cystic ﬁbrosis patients.
Variant 129G/C R117H 5T 7T 9T ΔF508 G551D N1303K G1349D
Effect on cDNA promoter 350G>A intron intron intron 1521_1523 delCTT 1652G>A 3909C>G 4046G>A (4178G>A)
GM11286 Hap 1 Hap 2
GM03465 Hap 1 Hap 2
GM11274 Hap 1 Hap 2
GM11279 Hap 1 Hap 1 Hap 1 Hap 2 Hap 2
GM11472 Hap 1 Hap 2 Hap 2 Hap 1
GM13591 Hap 1 Hap 1 Hap 2 Hap 2
Key: Hap 1 = Haplotype 1, Hap 2 = Haplotype 2
doi:10.1371/journal.pone.0118270.t001
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Fig 4. Droplet cluster identification and classification in the context of allelically cross-reacting fluorescence probes. (a,b) The two potential
haplotype configurations in a compound heterozygote. Primer pairs (arrows) are designed for both loci, and fluorescent probes are designed for the A allele
at locus A/a and the B allele at locus B/b. (c,d) Expected populations of droplets under the two potential haplotype configurations in panels a and b. Although
fluorescence probes are designed to one allele, they also fluoresce (at reduced intensity) in response to the other allele. For example, when a FAM-labeled
probe is designed to the A allele, droplets exhibit four levels of FAM fluorescence: the highest level for droplets containing only the A allele; a lower level for
droplets containing a mixture of A and a; a substantially lower level for droplets containing only a; and the lowest level for droplets containing neither A nor a
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Conclusions
We developed a method, Drop-Phase, for quickly evaluating the chromosomal phase of pairs
of DNA sequence variants by massively partitioning individual reaction vessels (wells) into
droplets and evaluating the co-partitioning of sequences into droplets. Drop-Phase is rapid (re-
quiring less than 4 hours), scalable (1–96 samples), and effective at substantial genomic dis-
tances (200 kb). Drop-Phase is also technically easy to perform and low in cost (S3 Table).
The genomic distance at which variants can be phased by Drop-Phase (200 kb, even in con-
ventionally extracted DNA samples) exceeds the lengths of 94% of human protein-coding
genes. Analyzing a series of pairs of genomic variants, with transitive inference of chromosom-
al phase, would allow phasing at still-larger scales, limited primarily by DNA quality and the
spacing of heterozygous sites in an individual’s genome. We believe that Drop-Phase could
thereby be used to phase variants of interest in almost any human gene.
Drop-Phase also has important limitations. Though it scales quickly to large numbers of
samples, it does not scale quickly to large numbers of loci, as each assay requires its own allele-
specific fluorescence probes and optimization. The primary application of Drop-Phase will
therefore be in phasing specific variants of interest to a researcher or clinical geneticist. These
variants will generally first be ascertained by other methods, such as whole-exome or whole-ge-
nome sequencing, gene-specific sequencing, or genome-wide genotyping. The genomic range
at which Drop-Phase can phase variants is limited by sample preparation; multi-well analysis
did not substantially extend this range beyond the distances reported here (data not shown),
and we believe that DNA extraction methods are the most promising way to extend genomic
range for applications for which longer-range phasing is important.
Drop-Phase will benefit allele-specific expression studies, identification of complex alleles
and compound heterozygotes, mapping of hard-to-resolve genome structures, characterization
of genome edits and de novomutations, and many other applications.
Supporting Information
S1 Fig. Molecular species contributing to droplets of each type, under linked and unlinked
scenarios.
(PDF)
S2 Fig. Physical intactness of DNA extracted using silica columns.
(PDF)
S3 Fig. Complex populations of droplet-clusters arising when allele-specific assays cross-
react with non-targeted alleles.
(PDF)
S4 Fig. Effect of DNA input concentration on droplet populations.
(PDF)
S1 Note. Mathematical relationships underlying linkage and droplet populations.
(PDF)
(S3 Fig.). When both SNP assays have this property, up to 16 (24) different patterns of fluorescence will be detected, depending on the presence or absence
in each droplet of targeted (A, B) alleles and non-targeted (a, b) alleles. Droplets arising from a single molecular species (e.g., the linked AB species) are
more common than droplets arising from combinations of molecules that happen by chance to appear in the same droplet (e.g., unlinked molecules
containing A and b). Arrowheads indicate common droplet populations that are diagnostic of the key linked species (AB and ab in the first individual; Ab and
aB in the second). (e,f) Drop-Phase data diagnostic of the two different haplotypic configurations in panels a and b. Arrowheads indicate the highly populated
clusters diagnostic of the linked species. Mathematical analysis of the droplet population sizes (S1 Note) is used to estimate the number of linked molecules
of each species and determine phase. S4 Fig. elaborates on the relationship of these droplet population sizes to DNA input concentration.
doi:10.1371/journal.pone.0118270.g004
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S1 Table. Assays used to assess physical linkage as a function of genomic distance.
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S3 Table. Laboratory costs associated with Drop-Phase.
(PDF)
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